Denmark-based Adcendo ApS has appointed Dominik Mumberg as chief scientific officer to help it advance its portfolio of antibody-drug conjugates (ADCs). Dr Mumberg holds a PhD in molecular biology from the University of Marburg in Germany and joins Adcendo from Bayer AG. His product development experience includes ADCs, targeted radiotherapies, biolotics and small molecules.
Adcendo announced the appointment on 3 May 2022.
Copyright 2022 Evernow Publishing Ltd